PD-1/PD-L1 axis importance and tumor microenvironment immune cells

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited targeted therapies.
• TNBC exhibits higher immunogenicity and immune cell infiltration compared to other breast cancer types.
• Immune checkpoint blockade therapies targeting the PD-1/PD-L1 axis have shown significant advances in cancer treatment.

Purpose of the Study:

• To review clinical trials of immunotherapy in various cancers, focusing on TNBC.
• To discuss the interplay between tumor-infiltrating immune cells and the breast tumor microenvironment.
• To explore novel strategies like CAR T-cell therapy and siRNA for TNBC targeted therapy.

Main Methods:

• Literature review of clinical trials and research studies on cancer immunotherapy.
• Analysis of immune cell infiltration and tumor microenvironment interactions in TNBC.
• Examination of signaling pathways regulating PD-L1 expression.

Main Results:

• Immunotherapy, particularly PD-1/PD-L1 blockade, demonstrates promising results in TNBC treatment.
• TNBC's immunogenic profile is a favorable marker for successful immunotherapy.
• CAR T-cell therapy and siRNA represent emerging strategies for targeted TNBC treatment.

Conclusions:

• Immunotherapy holds significant potential for improving outcomes in triple-negative breast cancer.
• Understanding the tumor immune microenvironment is crucial for optimizing immunotherapy efficacy.
• Novel therapeutic strategies are advancing the targeted treatment of TNBC.